The in-vitro pharmacology of PF-4522971 – A novel inhaled Muscarinic M3 Antagonist Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
The in vitro biology of PF-00610355 – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Demonstration of dual pharmacology in vivo of PF-3429281: A novel inhaled dual antimuscarinic/β2 agonist Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Nebulized bimosiamose – anti-inflammatory pan-selectin antagonist for the treatment of COPD Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009
Differential involvement of IκB kinases α and β in asthma and COPD Source: Annual Congress 2010 - COPD and asthma: models and human studies Year: 2010
Airway resistances: Raw , sRaw , sReff – Which is the best determinant of airway function? Source: Annual Congress 2010 - Lung function from infancy to adulthood Year: 2010
Treatment of sarcoidosis – pentoxifylline Source: Annual Congress 2009 - Pleural and parenchymal diseases Year: 2009
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010
Sensitivity and specificity of airway hyperreactivity (AHR) based on methacholine challenge (MCH) tests – Comparison of sGeff with FEV1 and MEF50 as target parameter Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012
A dual-acting muscarinic antagonist, ß2 -agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Adrenomedullin – a protective factor in asthma? Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009
Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Oral glucocorticoid treatment of severe asthma – Current practice in the US Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
The results of drug resistance survey of MDR-strains on second line drugs obtains in national reference laboratory – " M.Nasta " Institute – Bucharest Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Converse airway effects of nicotine in vitro and in vivo Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012
Effects of intratracheal pf-00610355, an inhaled β2 adrenoceptor agonist, in anaesthetised animals Source: Annual Congress 2009 - New bronchodilators Year: 2009